Choosing the first treatment for advanced bladder cancer

This study uses urine “omics” tests (detailed lab patterns from urine) to predict whether immunotherapy will work for people with metastatic urothelial (bladder/urinary tract) cancer. It may help doctors choose the right treatment sooner by identifying who is more likely to benefit.

This study looks back at medical records of people with advanced or metastatic urothelial cancer (a type of bladder or urinary tract cancer) who received the combination treatment EV+P as their first therapy. The goal is to understand how well this treatment works in real-world patients, which may help guide future treatment decisions.

This study looks at how well different treatments work for older adults with bladder cancer that has spread and who cannot take cisplatin. It also checks if geriatric assessments help guide care.

This Phase 2 study tests giving standard chemotherapy first, then immunotherapy, followed by major surgery to remove the bladder/urinary tumor and nearby lymph nodes. It’s for people with locally advanced urothelial cancer whose cancer has at least not worsened after initial chemotherapy.

This study tests whether adding surgery to remove the original bladder tumor and any remaining cancer spots can help people with advanced bladder cancer that has spread to only a few areas. It is for people who have already started a specific type of chemotherapy and whose cancer has not grown.

This trial tests whether adding targeted radiation therapy to standard drug treatment can help people with urothelial cancer that has spread to a few spots (up to 3 outside the brain). If you are starting your first or second round of systemic therapy, this study may be an option.